In vitro studies have established the synergistic anti-tumor effects of these two agents (80).A phase I clinical trial in 2019 assessed the safety and efficacy of the combination of SHR-1210 (an anti-PD-1 antibody) and apatinib in treating patients with advanced hepatocellular carcinoma, GC, or esophagogastric junction cancer. Here, PDCD1 is linked to neoplasm.